中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
16期
1566-1568
,共3页
袁芳%王立新%高金钗%杨霈龙
袁芳%王立新%高金釵%楊霈龍
원방%왕립신%고금차%양패룡
氯沙坦%原发性高血压%坎地沙坦%血尿酸
氯沙坦%原髮性高血壓%坎地沙坦%血尿痠
록사탄%원발성고혈압%감지사탄%혈뇨산
losartan%hypertension%candesartan%serum uric
目的：评价氯沙坦钾与坎地沙坦酯治疗原发性高血压合并高尿酸血症的临床疗效。方法80例原发性高血压合并高尿酸血症患者随机分为试验组40例和对照组40例，试验组口服氯沙坦钾50 mg? d－1，对照组口服坎地沙坦酯8 mg? d－1，2组疗程均为8周，比较2组患者治疗前后血尿酸和血压变化。结果与治疗前比较，试验组和对照组治疗后收缩压和舒张压的下降幅度分别为18．95／12．70 mmHg和27．18／13．03 mmHg，差异有统计学意义（ P＜0．05）。试验组降压总有效率为92．5％，对照组总有效率为95．0％，差异无统计学意义（P＞0．05）。试验组治疗后血尿酸水平为（431．98±56．11）μmol? L－1，较治疗前的（495．29±51．04）μmol? L－1明显降低（ P＜0．05）。对照组治疗前后血尿酸水平（486．79±60．81），（470．66±79．36）μmol? L－1差异无统计学意义（ P＞0．05）。试验组治疗前后血尿酸水平变化与收缩压水平变化呈正相关（r＝0．366，P＜0．05）。结论氯沙坦钾对原发性高血压伴高尿酸血症患者降压和降尿酸效果显著。
目的：評價氯沙坦鉀與坎地沙坦酯治療原髮性高血壓閤併高尿痠血癥的臨床療效。方法80例原髮性高血壓閤併高尿痠血癥患者隨機分為試驗組40例和對照組40例，試驗組口服氯沙坦鉀50 mg? d－1，對照組口服坎地沙坦酯8 mg? d－1，2組療程均為8週，比較2組患者治療前後血尿痠和血壓變化。結果與治療前比較，試驗組和對照組治療後收縮壓和舒張壓的下降幅度分彆為18．95／12．70 mmHg和27．18／13．03 mmHg，差異有統計學意義（ P＜0．05）。試驗組降壓總有效率為92．5％，對照組總有效率為95．0％，差異無統計學意義（P＞0．05）。試驗組治療後血尿痠水平為（431．98±56．11）μmol? L－1，較治療前的（495．29±51．04）μmol? L－1明顯降低（ P＜0．05）。對照組治療前後血尿痠水平（486．79±60．81），（470．66±79．36）μmol? L－1差異無統計學意義（ P＞0．05）。試驗組治療前後血尿痠水平變化與收縮壓水平變化呈正相關（r＝0．366，P＜0．05）。結論氯沙坦鉀對原髮性高血壓伴高尿痠血癥患者降壓和降尿痠效果顯著。
목적：평개록사탄갑여감지사탄지치료원발성고혈압합병고뇨산혈증적림상료효。방법80례원발성고혈압합병고뇨산혈증환자수궤분위시험조40례화대조조40례，시험조구복록사탄갑50 mg? d－1，대조조구복감지사탄지8 mg? d－1，2조료정균위8주，비교2조환자치료전후혈뇨산화혈압변화。결과여치료전비교，시험조화대조조치료후수축압화서장압적하강폭도분별위18．95／12．70 mmHg화27．18／13．03 mmHg，차이유통계학의의（ P＜0．05）。시험조강압총유효솔위92．5％，대조조총유효솔위95．0％，차이무통계학의의（P＞0．05）。시험조치료후혈뇨산수평위（431．98±56．11）μmol? L－1，교치료전적（495．29±51．04）μmol? L－1명현강저（ P＜0．05）。대조조치료전후혈뇨산수평（486．79±60．81），（470．66±79．36）μmol? L－1차이무통계학의의（ P＞0．05）。시험조치료전후혈뇨산수평변화여수축압수평변화정정상관（r＝0．366，P＜0．05）。결론록사탄갑대원발성고혈압반고뇨산혈증환자강압화강뇨산효과현저。
Objective To observe the clinical effect of losartan potassium and candesartan in the treatment of hypertension with hyperuricemia. Methods Total of eighty patients diagnosed with hypertension with hyperuricemia were randomly divided into two groups.The patients in experiment group ( n =40 ) were given losartan potassium 50 mg? d-1 , and the control group ( n =40 ) were given candesartan 8 mg? d -1 .The treatment lasted for 8 weeks.Serum uric acid levels and blood pressure levels were measured before and after treatment respectively. Results After treatment, the reduction of systolic blood pressure (SBP) and diatolic blood pressure(DBP) were 18.95/12.70 mmHg vs 27.18/13.03 mmHg in experiment and control group (P<0.05).The overall effective rations of experiment group and control group were not significant (92.5%vs 95.0%, P>0.05).After treatment, the level of uric aciddecreased apparently in experiment group [(431.98 ±56.11) vs (495.29 ±51.04) μmol? L-1, P <0.05]. There was no significance in uric acid level before and after treatment in control group [ ( 486.79 ±60.81 ) vs ( 470.66 ±79.36 ) μmol? L-1 , P>0.05 ] .There was a positive correlation between the range of uric acid level and the decrease of systolic blood pressure level ( r=0.366, P<0.05) in experiment group.Conclusion Losartan potassium is more useful than candesartan for hypertension with hyperuricemia.
